Clinical Trials on Type 1 Diabetes (Juvenile Onset) in Italy

Total 581 results

Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Boehringer Ingelheim

Completed

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Diabetes Mellitus, Type 2

United States, Austria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Norway, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Millennium Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
GlaxoSmithKline

Completed

AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes

Non-Insulin-Dependent Diabetes Mellitus

Spain, Germany, Belgium, United Kingdom, Ireland, Netherlands, Italy, France, Mexico, Switzerland, Lithuania
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Novo Nordisk A/S

Active, not recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

Diabetes Mellitus, Type 2

United States, Spain, Netherlands, United Kingdom, Canada, India, Austria, Korea, Republic of, Germany, Brazil, Malaysia, Thailand, Japan, Argentina, Serbia, Turkey, China, Russian Federation, Taiwan, Hong Kong, Mexico, Romania, Ukr... and more
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Japan, Italy, Denmark, Israel, Canada, France, India, Netherlands, Germany
Onconova Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (ONTIME)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | MDS | RAEB

United States, Belgium, Germany, Spain, France, Italy
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Bulgaria, Denmark, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, South Africa, Sweden, United Kingdom
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Canada, Colombia, Czech Republic, Finland, Hong Kong, India, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United...
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Belgium, Brazil, Canada, Czech Republic, Finland, Germany, Greece, Italy, Korea, Republic of, Mexico, Netherlands, Norway, Peru, Russian Federation, Slovakia, Spain, Taiwan
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, Italy, Puerto Rico, Hungary, Mexico, United States, India, Portugal, Taiwan, Brazil, Poland
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (IMAGINE 4)

Diabetes Mellitus, Type 2

Israel, Italy, Russian Federation, Turkey, Japan, Czechia, Spain, United Kingdom, United States, Australia, Hungary, Puerto Rico, Mexico, Austria, Germany, Denmark, Croatia, Greece, Romania, Taiwan, Brazil, Netherlands, Poland, Lithuania and more
Takeda

Terminated

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Narcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)

China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Eli Lilly and Company

Completed

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11)

Diabetes Mellitus, Type 2

Russian Federation, United States, Spain, Italy, Puerto Rico, Canada, Poland, Austria, Hungary, Israel, Greece, Taiwan, Argentina, Romania, Mexico, Slovakia
Amicus Therapeutics

Recruiting

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Pompe Disease (Late-onset)

United States, Japan, Taiwan, Australia, Canada, Italy, Germany
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Type 2 Diabetes | CKD | Overweight or Obesity

Italy, United States, United Kingdom, Canada, Spain
GlaxoSmithKline
Population Health Research Institute

Terminated

Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE)

Diabetes Mellitus, Type 2

United States, Germany, Russian Federation, Netherlands, South Africa, Sweden, Canada, Norway, United Kingdom, Latvia, Thailand, Colombia, India, Peru, Romania, Pakistan, Slovakia, Finland, Chile, Denmark, Argentina, Mexico, Czech Republic and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Eli Lilly and Company

Completed

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes (MOSAIc)

Diabetes Mellitus, Type 2

United States, Argentina, Brazil, Canada, China, Germany, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Puerto Rico, Russian Federation, Saudi Arabia, Spain, Turkey, United Arab Emirates, United Kingdom
GlaxoSmithKline

Completed

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Diabetes Mellitus, Type 2

United States, Germany, Canada, Belgium, Denmark, Spain, Ireland, Netherlands, United Kingdom, Hungary, Italy, France, Austria, Czechia, Norway, Finland, Sweden
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
Hoffmann-La Roche

Completed

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, France, Spain, Sweden, China, Korea, Republic of, United States, Canada, Germany, Ireland, Mexico, Poland, India, Denmark, Hungary, United Kingdom, New Zealand, Malaysia, Netherlands, Russian Federation, Thailand, Romania, Ita... and more
AstraZeneca
Bristol-Myers Squibb

Completed

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Diabetes Mellitus, Type 2

Australia, United States, Italy, Argentina, Canada, Mexico, India, Peru, Spain, Denmark, France, Singapore, Puerto Rico
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Narcolepsy Type 1

Spain, Japan, France, Germany, United States, Norway, Netherlands, Finland, Switzerland, Australia, Italy, Sweden
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
Novartis Pharmaceuticals

Completed

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Belgium, Hungary, Spain, Germany, Canada, Switzerland, Thailand, Korea, Republic of, United Kingdom, Italy, Austria, Sweden, France, United States
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
The George Institute
Servier

Completed

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study (ADVANCE-ON)

Diabetes Mellitus, Type 2

Australia, Canada, China, Czech Republic, Estonia, France, Germany, Hungary, India, Ireland, Italy, Lithuania, Malaysia, Netherlands, New Zealand, Philippines, Poland, Russian Federation, Slovakia, United Kingdom
Bayer

Completed

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone (ARTS-HF)

Heart Failure

France, Taiwan, United States, Turkey, Spain, Greece, Portugal, Germany, Canada, Austria, Czechia, Denmark, Israel, Korea, Republic of, Poland, South Africa, Sweden, Bulgaria, Italy, Finland, Hungary, Lithuania, Netherlands, Australia, ...
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
Novo Nordisk A/S

Active, not recruiting

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL)

Diabetes Mellitus, Type 2 | Chronic Kidney Disease

Spain, United States, Italy, Denmark, Poland, South Africa, Canada, France
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more

Clinical Trials on Type 1 Diabetes (Juvenile Onset) in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations